1Assistant Professor, Department of Biochemistry, C.G. Institute of Medical Sciences, Bilaspur, Chhattisgarh
2Assistant Professor, Department of Biochemistry, IGIMS, Patna, Bihar
3Associate Professor, Department of Pathology, C.G. Institute of Medical Sciences, Bilaspur, Chhattisgarh
4Assistant Professor, Department of Physiology, IGIMS, Patna, Bihar
*Corresponding author: Praveen Sablania, 4923/40, Raiger Pura, Karol Bagh, New Delhi, 110005. E-mail: sablaniapraveen@yahoo.com, Mobile: 09755138380
Online published on 31 January, 2015.
Cancer cervix is the most common cancer in women in developing countries like India. A number of studies have linked insulin resistance/C-peptide levels with endometrial cancer, breast cancer, and colorectal cancer. In the current study an attempt has been made to evaluate correlation between C-peptide (as endogenous maker of insulin secretion) & cervical cancer.
In this case-control study, we measured plasma C-peptide levels in cases and control subjects. 36 histologically proven carcinoma cervix cases (16 cases of Stage-I and 20 cases of Stage-II cancer cervix) and 41 controls matched with age & menopausal status and without evidence of adenocarcinoma cervix were included in the present study. Plasma levels of C-peptide were measured using an enzyme linked immunosorbent assay while statistical analysis was performed using SPSS.
Case subjects had statistically significant decrease in plasma mean values of C-peptide then control subjects [(3.69 ng/ml; 95% CI =3.08–4.30 ng/ml in cancer cases) versus (5.03 ng/ml; 95% CI = 4.36–5.70 ng/ml in controls)]; P = 0.004. Highest number of cases were observed in 1st quartile and lowest in 4th quartile with evidence of a significant trend (P=0.03).
C-peptide levels were found to be significantly reduced in non-obese, non-diabetic cancer cervix.
C-peptide, Cervical Carcinoma, Insulin, Insulin-like growth factor-I
